Open AccessNucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection
Author(s) -
Ke Yang,
Lin Wang,
LeQun Li,
JianHong Zhong
Publication year - 2014
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v6.i9.652
Subject(s) - medicine , hepatocellular carcinoma , hepatitis b virus , hepatitis b , chronic hepatitis , antiviral therapy , oncology , drug resistance , gastroenterology , surgery , virus , virology , microbiology and biotechnology , biology
Significant advances have been made in nucleos(t)ide analogue (NA) therapy to treat chronic hepatitis B, and this therapy reduces the risk of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) in some patients. However, whether NAs can also prevent recurrence after radical resection of HBV-related HCC remains controversial and is an important question, given that most patients will experience recurrence within a few years of curative surgery. Here we systematically reviewed the literature since 2004 on outcomes after administering NAs to patients with HBV-related HCC following radical resection. We focused on treatment indications, duration, effects on recurrence-free survival and overall survival, and the management of NA resistance. We find that patients with HCC should strongly consider NA therapy if they are positive for HBV-DNA, and that the available evidence suggests that postoperative NA therapy can increase both recurrence-free and overall survival. To minimize drug resistance, clinicians should opt for potent analogues with higher resistance barriers, and they should monitor the patient carefully for emergence of NA-resistant HBV.